Rexahn Pharma (RNN) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Roth Affirms Rexahn Pharma (RNN) at 'Buy'; Broad POC Program Initiation, Archexin Data in mRCC on Tap
November 3, 2015 11:49 AM ESTRoth Capital affirms Rexahn Pharma (NYSE: RNN) with a Buy rating and $3 price target after the company announced Q3 results and offered an update on operations today.
Analyst Joseph Pantginis noted that Rexahn's Q3 loss of $0.02 per share was flat with the firm's... More
